Table 1. The clinical and pathological characteristics of patients with invasive primary operable breast cancer and survival (relapse-free, cancer-specific and overall survival).
| Relapse-free survival | Cancer-specific survival | Overall survival | |||||
|---|---|---|---|---|---|---|---|
| Patients | Hazard ratio | P-value | Hazard ratio | P-value | Hazard ratio | ||
| (n=300) | (95% CI) | (95% CI) | (95% CI) | P-value | |||
| Age (⩽50/>50 years) | 67/233 | 2.52 (0.89-7.11) | 0.081 | 1.56 (0.54-4.54) | 0.416 | 2.60 (0.93 – 7.33) | 0.070 |
| Deprivation (1–2/3–5/6–7)* | 39/179/82 | 0.93 (0.75–1.14) | 0.485 | 1.01 (0.79–1.31) | 0.915 | 1.10 (0.90–1.36) | 0.360 |
| Type (special type/lobular/ductal) | 11/35/254 | 3.09 (0.83–11.55) | 0.094 | 14.97 (0.33–677.82) | 0.164 | 1.23 (0.59–2.60) | 0.583 |
| Size (⩽20/21–50/>50 mm) | 178/117/5 | 3.29 (1.83–5.94) | <0.0001 | 3.56 (1.74–7.26) | <0.0001 | 2.86 (1.62–5.06) | <0.0001 |
| Grade (I/II/III) | 56/148/95 | 2.23 (1.33–3.74) | 0.002 | 2.85 (1.46–5.58) | 0.002 | 1.74 (1.07–2.82) | 0.026 |
| Involved lymph node (0/1–3/>3) | 169/92/38 | 1.90 (1.25–2.88) | 0.003 | 2.37 (1.44–3.93) | 0.001 | 1.52 (1.01–2.30) | 0.046 |
| Hormonal receptor status (ER+ PR+/ER+ PR− or unknown/ER− PR− or unknown) | 116/122/62 | 2.61 (1.66–4.13) | <0.0001 | 2.76 (1.57–4.85) | <0.0001 | 1.94 (1.26–2.97) | 0.002 |
| White cell count (109 l−1)** | 7.0 (3.4–17.4) | 0.97 (0.83–1.15) | 0.755 | 0.94 (0.76–1.16) | 0.559 | 1.04 (0.89–1.21) | 0.619 |
| White cell count (<8.5/8.5–11/>11 × 109 l−1) | 230/53/13 | 0.81 (0.41–1.60) | 0.547 | 1.07 (0.52–2.21) | 0.857 | 1.36 (0.81–2.29) | 0.247 |
| Albumin concentration (g l−1)** | 44 (35–52) | 0.88 (0.78–0.99) | 0.035 | 0.82 (0.71–0.94) | 0.006 | 0.88 (0.78–0.98) | 0.026 |
| Albumin concentration (>43/⩽43 g l−1) | 155/114 | 3.39 (1.61–7.12) | 0.001 | 5.01 (1.85–13.57) | 0.002 | 3.23 (1.58–6.59) | 0.001 |
| C-reactive protein concentration (mg l−1)** | ⩽6 (⩽6–66) | 0.96 (0.88–1.04) | 0.293 | 0.97 (0.89–1.06) | 0.518 | 0.97 (0.90–1.04) | 0.391 |
| C-reactive protein (⩽10/>10 mg l−1) | 265/35 | 0.40 (0.10–1.68) | 0.211 | 0.62 (0.15–2.65) | 0.522 | 0.60 (0.19–1.95) | 0.395 |
| Loco-regional treatment (mastectomy or conservation surgery+radiotherapy/mastectomy+radiotherapy) | 221/79 | 3.70 (1.94–7.06) | <0.0001 | 5.51 (2.43–12.48) | <0.0001 | 2.40 (1.27–4.51) | 0.007 |
| Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none) | 150/86/52/9 | 2.03 (1.43–2.88) | <0.0001 | 2.59 (1.67–4.01) | <0.0001 | 1.93 (1.37–2.73) | <0.001 |
Abbreviations: CI, confidence interval; ER, oestrogen receptor; PR, progesterone receptor.
*Individual deprivation categories were used in the statistical analysis and **median (range).